WVE vs. URGN, AKBA, RAPT, MRNS, ARWR, XENE, IDYA, FOLD, PTCT, and MOR
Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include UroGen Pharma (URGN), Akebia Therapeutics (AKBA), RAPT Therapeutics (RAPT), Marinus Pharmaceuticals (MRNS), Arrowhead Pharmaceuticals (ARWR), Xenon Pharmaceuticals (XENE), IDEAYA Biosciences (IDYA), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), and MorphoSys (MOR). These companies are all part of the "pharmaceutical preparations" industry.
UroGen Pharma (NASDAQ:URGN) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.
UroGen Pharma presently has a consensus target price of $46.00, indicating a potential upside of 245.86%. Wave Life Sciences has a consensus target price of $11.17, indicating a potential upside of 80.69%. Given Wave Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe UroGen Pharma is more favorable than Wave Life Sciences.
Wave Life Sciences has a net margin of -54.61% compared to Wave Life Sciences' net margin of -123.74%.
91.3% of UroGen Pharma shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 11.1% of UroGen Pharma shares are held by insiders. Comparatively, 31.1% of Wave Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
UroGen Pharma received 8 more outperform votes than Wave Life Sciences when rated by MarketBeat users. Likewise, 73.29% of users gave UroGen Pharma an outperform vote while only 67.18% of users gave Wave Life Sciences an outperform vote.
Wave Life Sciences has higher revenue and earnings than UroGen Pharma. Wave Life Sciences is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Wave Life Sciences had 4 more articles in the media than UroGen Pharma. MarketBeat recorded 5 mentions for Wave Life Sciences and 1 mentions for UroGen Pharma. Wave Life Sciences' average media sentiment score of 1.87 beat UroGen Pharma's score of 1.15 indicating that UroGen Pharma is being referred to more favorably in the media.
UroGen Pharma has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.99, suggesting that its stock price is 199% less volatile than the S&P 500.
Summary
Wave Life Sciences beats UroGen Pharma on 9 of the 17 factors compared between the two stocks.
Get Wave Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Wave Life Sciences Competitors List
Related Companies and Tools